A new glossary of terms common in cancer trials can help site staff communicate more clearly with participants.

The FDA Oncology Center of Excellence’s Patient-Friendly Language Project has released a set of new definitions for terms cancer trial participants find difficult to understand, such as progression-free survival, blinded study, compassionate use, first-line therapy and dose escalation.

The list of more than 30 words and phrases can be used to help trial participants make more informed decisions about their care, the FDA says.

The glossary is available at https://bit.ly/3pByYyP.